Cellular Senescence Network (SenNet): Discovery, Validation Centers (UM1 Clinical Trials Not Allowed)
NIH Common Fund (NIH-CF) · NIH Institute/Center · RFA-RM-27-016
Source: Grants.gov · View original posting ↗
- AwardWhat a single award can be worth — the funder's published per-award amount or floor–ceiling range.
- Amount not listed
- DeadlineFinal application due date.
- Nov 23, 2026
- Letter of intentDue date for the letter of intent (a short pre-application some funders require or request before the full proposal).
- —
- MechanismNIH activity code — the grant type (R01 research project, R21 exploratory, K series career development, F series fellowship, …).
- UM1
- DurationMaximum project period for a single award.
- —
- Expected awardsHow many awards the funder anticipates making under this opportunity.
- 25
- Funding cycleHow often the program accepts applications (annual, multiple cycles per year, rolling, or one-time).
- One-time
- Open dateWhen applications open (or opened).
- Oct 9, 2026
- Total fundingThe overall pool the funder expects to commit across ALL awards under this opportunity — not what one project receives.
- —
- Clinical trialWhether proposed projects must, may, or must not include a clinical trial.
- Not allowed
Research areas
Auto-classified from the title and description (keyword-based) — may be imperfect.
Description
The purpose of this Notice of Funding Opportunity (NOFO) is to support SenNet Discovery and Validation Centers (SenNet DVCs) as a core component of Stage 2 of the NIH Common Fund Cellular Senescence Network (SenNet). Building on Stage 1 resources, DVCs will define, refine, and validate tissue- and disease-relevant cellular senescence signatures (“senotypes”) and associated biomarkers, and will investigate their functional consequences in human health and disease. DVCs are expected to generate and contribute high-quality molecular, cellular, and spatial datasets (including relevant metadata and documentation) and to use complementary experimental systems, as appropriate, to validate senotypes/biomarkers and characterize responses to senescence-associated perturbations or senotherapeutic approaches. DVC applications should also propose goals and aims for SenNet consortium-wide organizational and outreach activities (SenNet OOC functions).
Data notes: award amount not published in the source feed.